Medical technology company Sky Medical secures the prestigious King's Award for enterprise innovation, recognizing their groundbreaking geko device.
The Geko™ device, a groundbreaking wearable neuromuscular electro-stimulation (NMES) technology, is making waves in the healthcare industry for its role in enhancing chronic wound healing, particularly for venous leg ulcers and related conditions. This innovative device works by stimulating the common peroneal nerve below the knee, activating leg muscle pumps to increase venous, arterial, and microvascular blood flow to the wound site, thereby accelerating healing.
Key Benefits of the Geko™ Device
The Geko™ device is delivering real-world value in terms of clinical, operational, and economic aspects. Here are some key benefits:
- Improved healing rates: Clinical evaluations show the Geko device group healed wounds at a rate of 0.56 mm per week compared to 0.31 mm in control groups.
- Reduced time to wound closure: Average time reduced from 77 days to 40 days with the Geko device as an adjunct to compression therapy.
- Cost savings: Its application in primary care settings leads to substantial healthcare cost reductions by shortening healing times and reducing complications.
- Widespread clinical adoption: Demonstrated usefulness in integrated wound management, including autoimmune-related wounds such as vasculitis and psoriasis.
Recognition and Adoption
The Geko device has received numerous accolades, including the prestigious King's Award for Enterprise in Innovation for its breakthrough wound care technology. UK medical device innovator and manufacturer Sky Medical Technology Ltd, the creator of the Geko device, received this award in recognition of the exceptional work of their research, development, and commercial teams.
The Geko device is gaining traction among healthcare professionals for its non-invasive, easy-to-use design and efficacy in enhancing blood flow. It features prominently in educational and professional wound care events, such as WoundWISE Kitchener 2025, where it is showcased for its role in improving lower extremity circulation and reducing edema to promote healing.
Complementary Technologies
While the Geko device addresses vascular-related wound healing by improving physiological blood flow, newer technologies like biocompatible polymer-based sutureless tissue reconstruction (e.g., Tissium’s FDA-approved solution) represent complementary innovations in advanced wound and tissue repair, focusing on structural tissue integrity.
In Summary
The Geko device stands as a clinically validated, cost-effective, and increasingly adopted global healthcare tool for managing chronic wounds by restoring blood flow and accelerating healing. With strong evidence supporting its efficacy and impact on healthcare delivery, the Geko device is set to revolutionize the field of wound management.
- The use of the Geko™ device in the healthcare industry, with its focus on chronic wound healing and related medical-conditions, is a testament to the growing role of technology in health-and-wellness, particularly in medical plastics and patient care.
- The Geko device, a product of science and innovation, has been recognized for its breakthroughs in wound care technology, having received the King's Award for Enterprise in Innovation.
- In the realm of medical plastics and advanced wound and tissue repair, the Geko device, with its ability to improve blood flow, serves as a complementary technology to innovations like Tissium’s sutureless tissue reconstruction, focusing on structural tissue integrity.
